IRON — Disc Medicine, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1816736 ·
Last close
$76.57
Market Cap
$3.49B
52W High
$99.50
52W Low
$40.00
ADV30
1,354,627
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -64,161,000 -59,535,000 699,488,000 89,983,000 95,238,000
Jun 2026 0 — -65,075,000 -59,532,000 735,071,000 98,676,000 90,907,000
Mar 2026 0 — -69,524,000 -63,504,000 750,213,000 88,913,000 61,784,000
Dec 2025 0 — -66,970,000 -60,531,000 806,879,000 91,145,000 67,053,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-197,536,000
Investing CF
$-93,419,000
Financing CF
$262,296,000
CapEx
$-933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.54
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-633,222,000
Inventory
—
Receivables
—
ST Investments
$619,070,000
EBIT TTM
$-242,026,000
Pretax Income TTM
$-245,578,000
Interest Exp TTM
$3,552,000
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -236,022,000 -212,184,000 806,879,000 67,053,000 739,826,000 -180,393,000
Dec 2024 0 -129,720,000 -109,357,000 496,773,000 53,186,000 443,587,000 -93,926,000
Dec 2023 0 -91,125,000 -76,429,000 367,996,000 22,875,000 345,121,000 -73,462,000
Dec 2022 0 -47,475,000 -46,827,000 200,205,000 23,605,000 176,600,000 -42,252,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-245,888,000
OpCashFlow TTM
—
Assets (Latest)
$735,071,000
Forward EPS
$-6.82

Max Pain — expiry 2026-12-18

max pain strike: $75.00 · spot: $77.98 · call oi: 2,917 · put oi: 1,688
Expected Move to 2026-12-18: ±$9.95 (12.76%) — implied range $68.03 – $87.93 · ATM straddle on $80.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —
VKTX Viking Therapeutics, Inc. $3.43B $26.88 —

News headlines (Yahoo Finance, 1h cache)

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 13:30 · Yahoo
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
2026-11-04 14:05 · Yahoo
Disc Medicine to Participate in Upcoming Investor Conferences
2026-11-02 13:30 · Yahoo
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
2026-10-22 03:30 · Yahoo
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
2026-10-21 00:52 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan
2026-10-20 01:20 · Yahoo
Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus
2026-10-19 20:13 · Yahoo
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-10-19 20:01 · Yahoo
What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?
2026-10-19 19:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.